{"id":"investigational-varicella-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (erythema, swelling, pain)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Varicella vaccines work by presenting viral antigens (typically from attenuated or inactivated virus) to the immune system, triggering both humoral and cellular immune responses. This primes the body to rapidly recognize and neutralize varicella-zoster virus upon exposure, preventing chickenpox infection or reducing disease severity. GSK's investigational formulation likely represents an improved or alternative vaccine platform targeting varicella prevention.","oneSentence":"This vaccine stimulates the immune system to recognize and prevent varicella-zoster virus infection by inducing protective antibodies and cell-mediated immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:54.847Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of varicella (chickenpox)"}]},"trialDetails":[{"nctId":"NCT07481604","phase":"PHASE2","title":"Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"CHA Vaccine Institute Co., Ltd.","startDate":"2026-04","conditions":"Herpes Zoster","enrollment":135},{"nctId":"NCT04006808","phase":"PHASE1, PHASE2","title":"A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2019-10-25","conditions":"Herpes Zoster","enrollment":184},{"nctId":"NCT07406360","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-04-13","conditions":"Measles","enrollment":1209},{"nctId":"NCT07400003","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-01-06","conditions":"Herpes Zoster, mRNA Vaccine","enrollment":519},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06806137","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-05-15","conditions":"Chickenpox","enrollment":600},{"nctId":"NCT06855160","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-04-17","conditions":"Chickenpox","enrollment":900},{"nctId":"NCT06569823","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over","status":"RECRUITING","sponsor":"Dynavax Technologies Corporation","startDate":"2024-06-17","conditions":"Shingles, Herpes Zoster, Vaccine-Preventable Diseases","enrollment":764},{"nctId":"NCT05304351","phase":"PHASE2","title":"Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Curevo Inc","startDate":"2022-02-02","conditions":"Herpes Zoster, Shingles","enrollment":1516},{"nctId":"NCT05630846","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-12-14","conditions":"Measles; Mumps; Rubella; Chickenpox, Measles","enrollment":801},{"nctId":"NCT06961721","phase":"PHASE4","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2025-05","conditions":"Prevention of Herpes Zoster","enrollment":600},{"nctId":"NCT05966090","phase":"PHASE3","title":"A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-07-28","conditions":"Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections","enrollment":530},{"nctId":"NCT06581575","phase":"PHASE2","title":"A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immorna Biotherapeutics, Inc.","startDate":"2024-10-16","conditions":"Herpes Zoster (HZ), Infectious Diseases, Shingles","enrollment":467},{"nctId":"NCT06740630","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-01-10","conditions":"Chickenpox","enrollment":1840},{"nctId":"NCT06851832","phase":"PHASE1, PHASE2","title":"Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older","status":"RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-02-16","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":960},{"nctId":"NCT05084508","phase":"PHASE2","title":"A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-02-03","conditions":"Chickenpox","enrollment":800},{"nctId":"NCT05095701","phase":"PHASE4","title":"An Immunity Persistence Study of Live Attenuated Varicella Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-12-18","conditions":"Varicella","enrollment":703},{"nctId":"NCT06314724","phase":"PHASE3","title":"Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-02-29","conditions":"Varicella","enrollment":642},{"nctId":"NCT06484686","phase":"PHASE4","title":"An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-16","conditions":"Varicella","enrollment":414},{"nctId":"NCT06693895","phase":"PHASE3","title":"A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-26","conditions":"Chickenpox","enrollment":750},{"nctId":"NCT05991427","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2023-11-07","conditions":"Herpes Zoster","enrollment":65},{"nctId":"NCT06137755","phase":"PHASE1","title":"Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above","status":"RECRUITING","sponsor":"CHA Vaccine Institute Co., Ltd.","startDate":"2023-03-15","conditions":"Vaccine-Preventable Diseases, Herpes Zoster","enrollment":32},{"nctId":"NCT03894969","phase":"PHASE2","title":"Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-04-23","conditions":"Respiratory Disorders","enrollment":541},{"nctId":"NCT05871541","phase":"PHASE1","title":"A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine","status":"COMPLETED","sponsor":"Immorna Biotherapeutics, Inc.","startDate":"2023-05-26","conditions":"Herpes Zoster (HZ), Shingles, Infectious Disease","enrollment":75},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT05015686","phase":"PHASE3","title":"Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-09-30","conditions":"Varicella","enrollment":2400},{"nctId":"NCT05158777","phase":"PHASE3","title":"Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2022-02-13","conditions":"Varicella","enrollment":2480},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT05839301","phase":"PHASE3","title":"A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2023-04-27","conditions":"Varicella","enrollment":1200},{"nctId":"NCT05669625","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2022-12-26","conditions":"Varicella","enrollment":12440},{"nctId":"NCT05130398","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon","status":"COMPLETED","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2021-04-09","conditions":"Ebola Virus Disease","enrollment":120},{"nctId":"NCT01693380","phase":"PHASE4","title":"Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2009-05","conditions":"Influenza, Acute Respiratory Infection","enrollment":1742},{"nctId":"NCT05470855","phase":"PHASE4","title":"Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province","status":"UNKNOWN","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2022-07-06","conditions":"Varicella","enrollment":45400},{"nctId":"NCT05245838","phase":"PHASE1","title":"Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2022-01-10","conditions":"Shingles, Herpes Zoster, Vaccine-Preventable Diseases","enrollment":150},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT05150392","phase":"PHASE3","title":"An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2018-07-11","conditions":"Varicella","enrollment":1193},{"nctId":"NCT03375502","phase":"PHASE2, PHASE3","title":"A Study of MG1111 in Healthy Children","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2016-11-26","conditions":"Healthy Children","enrollment":814},{"nctId":"NCT00861744","phase":"PHASE2","title":"Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-03","conditions":"Rubella, Mumps, Measles","enrollment":1259},{"nctId":"NCT01702428","phase":"PHASE3","title":"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-09","conditions":"Rubella, Measles, Mumps","enrollment":5016},{"nctId":"NCT00092430","phase":"PHASE3","title":"Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-09-26","conditions":"Measles, Mumps, Rubella","enrollment":1200},{"nctId":"NCT00535236","phase":"PHASE1","title":"A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11-02","conditions":"Herpes Zoster, Herpes Zoster-related Complications","enrollment":341},{"nctId":"NCT03555071","phase":"PHASE3","title":"A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2014-04-07","conditions":"Varicella","enrollment":1197},{"nctId":"NCT00969436","phase":"PHASE3","title":"Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-09","conditions":"Varicella, Rubella, Mumps","enrollment":450},{"nctId":"NCT01086449","phase":"PHASE1","title":"Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03-04","conditions":"Herpes Zoster","enrollment":20},{"nctId":"NCT00920218","phase":"PHASE2","title":"Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07-14","conditions":"Herpes Zoster","enrollment":121},{"nctId":"NCT02965404","phase":"PHASE1","title":"A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2016-04","conditions":"Varicella","enrollment":270},{"nctId":"NCT02981836","phase":"PHASE3","title":"A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2016-08","conditions":"Varicella","enrollment":5997},{"nctId":"NCT00560755","phase":"PHASE3","title":"Safety Study of ProQuad® rHA in Infants (V221-037)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10-24","conditions":"Measles, Mumps, Rubella","enrollment":3388},{"nctId":"NCT00109122","phase":"PHASE2","title":"Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-11","conditions":"Shingles","enrollment":180},{"nctId":"NCT00092417","phase":"PHASE3","title":"Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-10","conditions":"Healthy","enrollment":695},{"nctId":"NCT00231816","phase":"PHASE3","title":"A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":"Herpes Zoster","enrollment":763},{"nctId":"NCT00322231","phase":"PHASE3","title":"A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":"Herpes Zoster","enrollment":101},{"nctId":"NCT00130793","phase":"PHASE3","title":"A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":"Herpes Zoster","enrollment":368},{"nctId":"NCT00192491","phase":"PHASE3","title":"Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2000-12","conditions":"Influenza","enrollment":1200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Investigational varicella vaccine","genericName":"Investigational varicella vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to recognize and prevent varicella-zoster virus infection by inducing protective antibodies and cell-mediated immunity. Used for Prevention of varicella (chickenpox).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}